28 January 2022 in Journal of Thrombosis and Haemostasis
Patients with severe hemophilia A (HA) have an increased risk of spontaneous and trauma-related bleeding due to a congenital absence of factor VIII (FVIII). Most severe HA patients use prophylactic FVIII concentrate which effect can be monitored with FVIII activity level measurement. However, FVIII activity level is less valuable in predicting the potential clinical bleeding risk. Some patients still experience breakthrough bleeds despite adequate FVIII trough levels, while others do not bleed with trough levels below threshold. This difference may be caused by inter-individual differences in pro- and anticoagulant factors, the so-called hemostatic balance. Thrombin generation assays (TGAs) measure the hemostatic balance as a whole. Thereby, the TGA may be a better tool in the guidance and monitoring of treatment in HA patients. In addition, TGAs offer the opportunity to determine the response to bypassing agents (BPAs) and treatment with non-factor replacement therapy, where FVIII activity assays are not suitable for monitoring. This review summarizes the current knowledge about monitoring different HA treatment modalities by TGA, as single treatment option and when used in a concomitant fashion.
1 January 2025 in The Journal of Haemophilia Practice
Introduction: Emicizumab has recently been investigated for prophylactic use in patients with acquired haemophilia A. While it shows promising results in effectively reducing bleeding episodes, there remains a very delicate question concerning the risk of thromboembolic events. Recently published prospective studies reported thrombotic events in 4% to 8% of cases. However, these studies excluded patients with an increased thrombotic risk or those undergoing treatment for a thromboembolic disease, situations frequently occurring in this elderly patient group. Therefore, we urge clinicians to critically assess which patients would benefit from emicizumab treatment and which would not. Case series: Here, we present a case series from a Dutch haemophilia treatment centre that highlights the complexity of patients currently managed with acquired haemophilia A. The series discusses individual patient characteristics, underlying comorbidities, and responses to initiated therapy with bypassing agents and immunosuppressive therapy. The pros and cons of emicizumab therapy in these individual patients are discussed. Discussion: We suggest considering the use of emicizumab in patients with acquired haemophilia A through a personalised approach. This approach involves assessing thrombotic risk on one hand and focusing on controlling bleeding on the other. It should account for the need to rapidly eradicate the inhibitor in cases of acute bleeding necessitating bypassing agents. Alternatively, it should consider the possibility of postponing or reducing immunosuppressive therapy in frail patients without overt bleeding, for whom emicizumab presents an ideal prophylactic option.